Biolidics

Biolidics issues 17.9 mil shares at 17.5 cents per share in placement exercise to raise $3.1 mil

SINGAPORE (Sept 10): Biolidics has entered into an agreement with the Genome Institute of Singapore (GIS) to collaborate and develop a new and innovative liquid biopsy test in the field of circulating tumour cells (CTCs) for the assessment of minimal resi

SINGAPORE (June 25): Medical technology company Biolidics has entered into a partnership with Zhongshan TopGene Medical Laboratory Co to develop and commercialise laboratory-developed tests (LDTs) in the field of circulating tumour cells (CTCs) using Biol

SINGAPORE (Mar 27): CGS-CIMB is starting coverage of biotech firm Biolidics at “add” given it has developed a game-changing liquid biopsy kit for cancer.

SINGAPORE (Dec 19): Just two hours into its debut on the Singapore Exchange (SGX) Catalist board, shares in medical technology firm Biolidics have slumped 23.2% from its listing price of 28 cents.

SINGAPORE (Dec 11): Medtech company Biolidics is selling 27.5 million new shares at 28 cents each to retail and institutional investors in a private placement ahead of its listing on the Catalist Board of the Singapore Exchange.

SINGAPORE (Nov 26): Biolidics, a cancer diagnostic solutions developer and an associate company of Clearbridge Health, on Friday lodged a preliminary prospectus for a planned initial public offering (IPO) on the Singapore Exchange's Catalist board.